Search

Author/Creator van der Vegt, A N

1. OS05.7.A Absence of severe hematological toxicity during first line treatment predicts low chance on severe toxicity during second line alkylating chemotherapy in glioblastoma. (9th September 2021)

Authors:
van den Elzen, F E L; Grun, N; Osinga, J; van der Vegt, A N; de Glopper, L; Sintemaartensdijk, M; van Linde, M E; Postma, T J; Schuur, M; Kouwenhoven, M C M
Journal:
Neuro-oncology
Issue:
Volume 23: Supplement 2 (2021)
Page Start:
ii8
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. P14.13 Severe hematological toxicity during chemoradiation for glioblastoma: Identification of clinical and pharmacological risk factors and consequences for the individual patient. (9th September 2021)

Authors:
Grun, N; den Otter, C A; Sintemaartensdijk, M; Osinga, J; van den Elzen, F E L; van der Vegt, A N; de Haan, J; Bruynzeel, A M E; van Linde, M E; Postma, T J; Schuur, M; de Witt Hamer, P C; De Vos, F Y F L; Verhoeff, J J C; Jongen, J L M; Lissenberg-witte, B I; Kouwenhoven, M C M
Journal:
Neuro-oncology
Issue:
Volume 23: Supplement 2 (2021)
Page Start:
ii40
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search